Symbols

JAZZ

Jazz Pharmaceuticals·NASDAQ

--(--)

JAZZ fundamentals

JAZZ Q4 2025 Earnings

Jazz Pharmaceuticals (JAZZ) released its earnings on Feb 24, 2026: revenue was 1.20B (YoY +10.09%), beat estimates; EPS was 6.64 (YoY +0.61%), beat estimates.

Revenue / YoY

1.20B

+10.09%

EPS / YoY

6.64

+0.61%

Report date

Feb 24, 2026

JAZZ Earnings Call Summary for Q4,2025

Revenue Milestone: 2025 total revenue of $4.3B, Q4 record $1.2B (+10% YoY), driven by rare oncology and new launches.
Pipeline Success: Zanidatamab Phase III data shows 2+ years OS in GEA; Modeyso generates $48M in 8 months.
Financial Health: Strong cash ($2.4B), 2026 guidance for $4.25B-$4.5B revenue, 90-91% gross margin.
Strategic Moves: Sold priority voucher for $100M, resolved litigation extending patent runway, and investing $725M-$775M in R&D.

Earnings

EPS

Revenue

Revenue & Expenses

JAZZ has released its 2025 Q4 earnings report, with revenue of 1.20B, reflecting a YoY change of 10.09%, and net profit of 203.45M, showing a YoY change of 6.45%. The Sankey diagram below clearly presents JAZZ's revenue sources and cost distribution.

Key Indicators

Jazz Pharmaceuticals (JAZZ) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Jazz Pharmaceuticals (JAZZ)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Jazz Pharmaceuticals (JAZZ)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Jazz Pharmaceuticals (JAZZ)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown